|
|
Article: Panacos Announces Results of Bevirimat Prospective Study, which Confirm Patient Response Predictors.(Clinical report)
- Article from:
- Business Wire
- Article date:
- June 17, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Completed Phase 2b Extension Study Determines Likely Phase 3 Patient Profile
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) today announced the completion of a Phase 2b prospective study of bevirimat in treatment-experienced and treatment-naive patients that confirms the recently discovered factors that predict response to bevirimat, its lead HIV maturation inhibitor. With 14 days of bevirimat treatment, patients with the predictors of response had a statistically significant higher mean viral load reduction than patients with polymorphisms (variants) at Gag amino acid positions 369, 370 or 371.
Treatment-experienced patients who had ...